Hellenic journal of nuclear medicine最新文献

筛选
英文 中文
18F-FDG PET/CT characterization and response evaluation in a case of lymphomatoid granulomatosis involving the main pulmonary artery. 一例累及主肺动脉的淋巴肉芽肿病的 18F-FDG PET/CT 特征和反应评估。
IF 1.5 4区 医学
Hellenic journal of nuclear medicine Pub Date : 2024-04-18 DOI: 10.1967/s002449912709
Lanlan Cui, Zhimin Wang, Weidong Hu, Huichun Wang
{"title":"18F-FDG PET/CT characterization and response evaluation in a case of lymphomatoid granulomatosis involving the main pulmonary artery.","authors":"Lanlan Cui, Zhimin Wang, Weidong Hu, Huichun Wang","doi":"10.1967/s002449912709","DOIUrl":"https://doi.org/10.1967/s002449912709","url":null,"abstract":"Main pulmonary artery (MPA) involvement of lymphomatoid granulomatosis (LYG) is extremely rare. We described fluorine-18-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) findings in a case with LYG originated from the MPA. Fluorine-18-FDG PET/CT demonstrated nodular hypermetabolic foci in the MPA, corresponding well to the intraluminal filling defects on CT pulmonary angiography, and the secondary right heart dysfunction was observed. Final diagnosis was made after transcatheter MPA biopsies and multi-disciplinary consultation. The patient recovered completely following the steroid therapy and MPA stenting, which was illustrated on the second 18F-FDG PET/CT.","PeriodicalId":12871,"journal":{"name":"Hellenic journal of nuclear medicine","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140686162","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Early evaluation of CAR-T cell therapy response in R/R DLBCL patients using 18F-FDG PET/CT. 使用 18F-FDG PET/CT 对 R/R DLBCL 患者的 CAR-T 细胞疗法反应进行早期评估。
IF 1.5 4区 医学
Hellenic journal of nuclear medicine Pub Date : 2024-04-18 DOI: 10.1967/s002449912701
Kazuhiro Kitajima, Hiroyuki Yokoyama, Reona Wada, Yukihisa Tamaki, K. Yoshihara, K. Kaida, Satoshi Yoshihara, K. Yamakado
{"title":"Early evaluation of CAR-T cell therapy response in R/R DLBCL patients using 18F-FDG PET/CT.","authors":"Kazuhiro Kitajima, Hiroyuki Yokoyama, Reona Wada, Yukihisa Tamaki, K. Yoshihara, K. Kaida, Satoshi Yoshihara, K. Yamakado","doi":"10.1967/s002449912701","DOIUrl":"https://doi.org/10.1967/s002449912701","url":null,"abstract":"OBJECTIVE\u0000CD19-targeted chimeric antigen receptor T (CAR-T) cell therapy provides a durable response in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). The role of fluorine-18-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) for early evaluation of responsein patients with that immunotherapy was evaluated.\u0000\u0000\u0000SUBJECTS AND METHODS\u0000Three separate 18F-FDG PET/CT examinations of 53 patients (29 males, 24 females; median 62 years old) with R/R DLBCL were conducted; before bridging therapy [time of decision (TD)], before CAR-T (tisagenlecleucel, n=37; lisocabtagenemaraleucel, n=16) infusion [time of CAR-T infusion (IT)], and one month (M1) after CAR-T infusion. Response was evaluated based on the Deauville 5-point scale and Lugano criteria.\u0000\u0000\u0000RESULTS\u0000Among 21 patients (39.6%) with complete metabolic response (CMR) at IT-PET, 20 were able to continue CMR, while one showed progression at M1-PET. Among 32 patients (60.4%) with non-CMR at IT-PET, 12, 8, 4, and 8 showed CMR, partial metabolic response (PMR), (non-metabolic response (NMR), and progressive metabolic disease (PMD), respectively, at M1-PET as compared with IT-PET. Evaluations of M1-PET as compared with baseline TD-PET indicated 32, 7, 5, and 9 patients with CMR, PMR, NMR, and PMD, respectively. After a median 10.1 months, 26 patients showed progression and 13 had died from DLBCL. The 32 who achieved CMR showed significantly longer progression-free (P<0.0001) and overall survival (P<0.0001) periods as compared to the 21 non-CMR patients.\u0000\u0000\u0000CONCLUSION\u0000Fluorine-18-FDG PET/CT findings obtained one month after CAR-T cell therapy showed accuracy for early response evaluation and prediction of progression in patients with R/R DLBCL.","PeriodicalId":12871,"journal":{"name":"Hellenic journal of nuclear medicine","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140686494","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
225Ac-DOTATATE therapy in a case of metastatic atypical lung carcinoid. 225Ac-DOTATATE 治疗一例转移性非典型肺类癌。
IF 1.5 4区 医学
Hellenic journal of nuclear medicine Pub Date : 2024-04-18 DOI: 10.1967/s002449912706
Lanying Li, Jiao Ma, Songsong Yang, Chunyin Zhang
{"title":"225Ac-DOTATATE therapy in a case of metastatic atypical lung carcinoid.","authors":"Lanying Li, Jiao Ma, Songsong Yang, Chunyin Zhang","doi":"10.1967/s002449912706","DOIUrl":"https://doi.org/10.1967/s002449912706","url":null,"abstract":"","PeriodicalId":12871,"journal":{"name":"Hellenic journal of nuclear medicine","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140685953","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Assessing PET/CT's diagnostic accuracy in idiopathic myopathies. 评估 PET/CT 对特发性肌病的诊断准确性。
IF 1.5 4区 医学
Hellenic journal of nuclear medicine Pub Date : 2024-01-01 DOI: 10.1967/s002449912711
Feng Liang, Guanxi Li, Junhong Guo, Wei Zhang, Xueli Chang
{"title":"Assessing PET/CT's diagnostic accuracy in idiopathic myopathies.","authors":"Feng Liang, Guanxi Li, Junhong Guo, Wei Zhang, Xueli Chang","doi":"10.1967/s002449912711","DOIUrl":"10.1967/s002449912711","url":null,"abstract":"<p><strong>Objective: </strong>Recent studies have utilized fluorine-18-fluorodeoxyglucose (<sup>18</sup>F-FDG) positron emission tomography/computed tomography (PET/CT) specifically to diagnose cases of idiopathic inflammatory myopathies (IIM), excluding inclusion body myositis (IBM). Conversely, carbon-11 (<sup>11</sup>C) labeled Pittsburgh compound B (PIB)-PET imaging is exclusively used for the detection of IBM. This research is designed to evaluate the diagnostic accuracy of PET/CT in identifying IIM by employing rigorous diagnostic accuracy testing methodologies.</p><p><strong>Materials and methods: </strong>A systematic review and meta-analysis were conducted across multiple databases including PubMed, and Embase. We focused on the diagnostic utility of PET/CT in IIM, assessing sensitivities, specificities, and deriving likelihood ratios (LR+ and LR-). The study was registered with PROSPERO (CRD42022343222).</p><p><strong>Results: </strong>This systematic review identified 635 citations, of which 10 eligible trials were included, with a total of 419 participants. The results indicated a sensitivity of 0.86 (0.81-0.90), and a specificity of 0.93 (0.88-0.96). The synthesis of LR revealed the LR+ of 10.35 (6.31-16.98), and LR-of 0.15 (0.07-0.32). The summary receiver operating characteristic curve (SROC) showed an area under the curve (AUC) of 0.9658. Regarding IBM, the sensitivity was 0.84 (0.60-0.97), and the specificity was 1 (0.69-1). The synthesis of LR showed the LR+ of 9.61 (1.46-63.15) and an LR- of 0.21 (0.09-0.51). For disease activity, the sensitivity was 0.96 (0.92-0.99), and the specificity was 0.91 (0.084-0.96). The synthesis of LR showed an LR+ of 9.43 (5.39-16.51) and an LR- of 0.05 (0.02-0.11).</p><p><strong>Conclusion: </strong>Positron emission tomography/CT has great potential for accurately diagnosing and monitoring patients with IIM, and may have implications for their clinical management.</p>","PeriodicalId":12871,"journal":{"name":"Hellenic journal of nuclear medicine","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140849155","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
PET/CT findings and dose distribution during radiotherapy in T1N0M0-T2N0M0 glottic cancer. T1N0M0-T2N0M0声门癌放疗期间的 PET/CT 发现和剂量分布。
IF 1.5 4区 医学
Hellenic journal of nuclear medicine Pub Date : 2024-01-01 DOI: 10.1967/s002449912710
Yukinori Okada, Tatsuhiko Zama, Tomohiro Itonaga, Ryuji Mikami, Mitsuru Okubo, Shinji Sugahara, Masahiko Kurooka, Motoki Nakai, Koichiro Abe, Mana Yoshimura, Kazuhiro Saito
{"title":"PET/CT findings and dose distribution during radiotherapy in T1N0M0-T2N0M0 glottic cancer.","authors":"Yukinori Okada, Tatsuhiko Zama, Tomohiro Itonaga, Ryuji Mikami, Mitsuru Okubo, Shinji Sugahara, Masahiko Kurooka, Motoki Nakai, Koichiro Abe, Mana Yoshimura, Kazuhiro Saito","doi":"10.1967/s002449912710","DOIUrl":"https://doi.org/10.1967/s002449912710","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the positron emission tomography/computed tomography (PET/CT) findings of T1/T2N0M0 glottic cancer (hereafter referred to as T1/T2) and dose distribution in radiotherapy.</p><p><strong>Subjects and methods: </strong>We retrospectively collected data from patients diagnosed with T1/T2N0M0 glottic cancer who received radiotherapy. The extent of fluorine-18-fluorodeoxyglucose (<sup>18</sup>F-FDG) accumulation in primary tumors, maximum standardized uptake value (SUVmax), total lesion glycolysis (TLG), tumor volume of primary tumors on PET/CT were compared. Furthermore, the tumor identified on PET/CT was incorporated into the radiotherapy plans. A dummy plan (radiation field 6x6cm, prescription point facing the vertebral body, maximum dose ≤107%, T1/T2 66Gy/33 fractions) was developed for three-dimensional conformal radiotherapy, and the dose distribution of primary tumors was calculated.</p><p><strong>Results: </strong>Twenty-nine patients (27 men and two women) were included; their mean age was 67.2±15.0 years. Increased <sup>18</sup>F-FDG accumulation in primary tumors was observed on PET/CT in 22/29 (78.5%; T1: 14/21 [67%], T2: 8/8 [100%]) patients. The median SUVmax, TLG, and primary tumor volume were significantly different between T1 and T2 (SUVmax, T1: 4.56 vs. T2: 8.43, P=0.035; TLG, T1: 1.01 vs. T2: 3.71 SUVxmL, P<0.01; primary tumor volume, T1: 0.38mL vs. T2: 0.80mL, P=0.01). At a TLG cut-off value of 3.470, the area under the curve was 0.875, sensitivity was 0.875, and specificity was 0.929 for T1-T2 differentiation. In 20 patients with <sup>18</sup>F-FDG accumulation, the minimum radiation dose was significantly different between T1 and T2 (66Gy vs. 64Gy, P<0.01) at the same 66Gy prescription. The minimum radiation dose and primary tumor volume show the correlation value (r=-0.516, P=0.02).</p><p><strong>Conclusion: </strong>In glottic cancer, T1 and T2 can be differentiated by the extent of <sup>18</sup>F-FDG accumulation in primary tumors on PET/CT. The minimum radiation dose rate decreases as volume increases.</p>","PeriodicalId":12871,"journal":{"name":"Hellenic journal of nuclear medicine","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140851205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lutetium-177-PSMA-617 radioligand therapy in patients with high volume metastatic prostate cancer prior to chemotherapy and new generation androgen deprivation therapy: Clinical Experience. 在化疗和新一代雄激素剥夺疗法之前对高体积转移性前列腺癌患者进行镥-177-PSMA-617放射性配体治疗:临床经验。
IF 1.5 4区 医学
Hellenic journal of nuclear medicine Pub Date : 2023-09-01 Epub Date: 2023-12-14 DOI: 10.1967/s002449912603
Yusuf Zeki Celen, Umut Elboga, Ertan Sahin, Tulay Kus, Merve Okuyan, Yusuf Burak Cayirli, Sakip Erturhan, Ufuk Cimen
{"title":"Lutetium-177-PSMA-617 radioligand therapy in patients with high volume metastatic prostate cancer prior to chemotherapy and new generation androgen deprivation therapy: Clinical Experience.","authors":"Yusuf Zeki Celen, Umut Elboga, Ertan Sahin, Tulay Kus, Merve Okuyan, Yusuf Burak Cayirli, Sakip Erturhan, Ufuk Cimen","doi":"10.1967/s002449912603","DOIUrl":"10.1967/s002449912603","url":null,"abstract":"<p><strong>Objective: </strong>We aimed to evaluate the efficacy oflutetium-177-prostate-specific membrane antigen-617 (<sup>177</sup>Lu-PSMA-617) with the luteinizing hormone releasing hormone (LHRH) analogues in the first or in the second-line setting formetastatic castration sensitive patients and metastatic castration resistance after progression with LHRH analogues.</p><p><strong>Subjects and methods: </strong>Sixteen consecutive patients with high volume metastatic prostate cancer undergone <sup>177</sup>Lu-PSMA-617 therapy who were refused chemotherapy and were unable to use new generation anti-androgen drugs because of unavailibility of reimbursement, were included in this retrospective study. Prostate specific antigen (PSA) response (>50% decrease), disease control rate (DCR: complete or partial response), progression-free survival (PFS) and overall survival (OS) were calculated to evaluate according to the clinicopathological features of the patients. Treatment response evaluated by <sup>68</sup>Ga-PSMA-11 positron emission tomography/computed tomography (PET/CT).</p><p><strong>Results: </strong>Mean age was 74,6 (SD±8,36). Among them, 7 (43,8%) patients has castration resistant disease, while the remaining has castration sensitive disease. Lutetium-177-PSMA-617 was administered to 10 (62,5%) patients as one of the first-line treatment and 6 patients received the treatment after progression on LHRH as a second-line treatment. Considering all patients, PSA response rate and DCR were 50% and 62% respectively. The median PFS and OS (with 95% CI) were 11,2 months (11-15) and 29 months (25,6-32,4), respectively in patients treated with <sup>177</sup>Lu-PSMA-617 and LHRH analogues. Clinicopathological features and basal PSA level did not have effect on PSA response rates, DCR, OS and PFS. On the other hand, increment in PFS and OS (with 95% CI) was observed in castration resistant disease and in the second-line therapy; for castration resistant disease 16,5 months (12.3-19.7); 30 months (25.3-32.7), for the second-line therapy 14.5 months (12-20.5); 29 months (NR), respectively but statistically not significant. Serious toxicity was observed in a limited number of patients (18,7%), treatment-related death was not observed.</p><p><strong>Conclusion: </strong>Favorable results can be achived with second-line <sup>177</sup>Lu-PSMA-617 treatment in terms of OS and PFS, especially in castration-resistant disease, when chemotherapy and new generation ADT's cannot be used.</p>","PeriodicalId":12871,"journal":{"name":"Hellenic journal of nuclear medicine","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138802917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Automatic synthesis of 18F-AV-45 and its clinical application in Alzheimer's disease. 18F-AV-45 的自动合成及其在阿尔茨海默病中的临床应用。
IF 1.5 4区 医学
Hellenic journal of nuclear medicine Pub Date : 2023-09-01 DOI: 10.1967/s002449912610
Qiang Xie, Kai-Xuan Wang, Xing-Xing Zhu, Ji-Kui Xie, Ming Ni
{"title":"Automatic synthesis of <sup>18</sup>F-AV-45 and its clinical application in Alzheimer's disease.","authors":"Qiang Xie, Kai-Xuan Wang, Xing-Xing Zhu, Ji-Kui Xie, Ming Ni","doi":"10.1967/s002449912610","DOIUrl":"10.1967/s002449912610","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the automatic synthesis of β-amyloid (Aβ) positron emission tomography (PET) imaging agent (E) -4- (2- (6- (2- (2-<sup>18</sup>F fluoroethoxy) ethoxy) ethoxy) pyridine-3-yl) vinyl) - N-methylaniline (<sup>18</sup>F-AV-45) for the diagnosis of Alzheimer's disease (AD) and its clinical application in AD patients.</p><p><strong>Materials and methods: </strong>Fluorine-18-AV-45 was synthesized with AV-105 as the precursor, and the factors affecting the synthesis efficiency, such as the amount of precursor, nucleophilic reaction temperature were studied. At the same time, <sup>18</sup>F-AV-45 PET/computed tomography (CT) brain scanning was performed in 15 patients with dementia to determine whether AD was the cause of the dementia.</p><p><strong>Results: </strong>After optimizing the parameters, it was discovered that the highest synthesis efficiency was achieved with a AV-105 dosage of 2mg, a reaction temperature of 130<sup>o</sup>C, and 1mL of DMSO. The radiochemical yield (RCP) was greater than 98, and the uncorrected synthesis efficiency was about 31.0%±2.8%. Ten of the 15 patients with dementia showed positive Aβ protein deposition, and the main deposition site of the imaging agent was the gray matter area of the brain, which was consistent with AD diagnosis, while the other 5 patients showed negative Aβ protein deposition, suggesting non-AD dementia.</p><p><strong>Conclusion: </strong>β-amyloid protein <sup>18</sup>F-AV-45 imaging agent can be easily and quickly prepared by the All in One radiochemical synthesis module. Our preliminary results offer hope that it can effectively detect β-amyloid deposition in the brain of AD patients in order to determine the etiology of dementia.</p>","PeriodicalId":12871,"journal":{"name":"Hellenic journal of nuclear medicine","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139039755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
SPECT/CT SUV-based metrics: A promising diagnostic tool in classifying patients with suspected transthyretin cardiac amyloidosis among the different Perugini grades? 基于SPECT/CT SUV的指标:将疑似转甲状腺素心脏淀粉样变性患者划分为不同佩鲁吉尼分级的有前途的诊断工具?
IF 1.5 4区 医学
Hellenic journal of nuclear medicine Pub Date : 2023-09-01 Epub Date: 2023-12-14 DOI: 10.1967/s002449912601
Sophia Koukouraki, Nikolaos Kapsoritakis, Olga Bourogianni, Maria Stathaki, Ioannis Zaganas, Alexandros Patrianakos, Anthi Plevritaki, Dafni Korela, Maria Marketou, Emmanouil Foukarakis
{"title":"SPECT/CT SUV-based metrics: A promising diagnostic tool in classifying patients with suspected transthyretin cardiac amyloidosis among the different Perugini grades?","authors":"Sophia Koukouraki, Nikolaos Kapsoritakis, Olga Bourogianni, Maria Stathaki, Ioannis Zaganas, Alexandros Patrianakos, Anthi Plevritaki, Dafni Korela, Maria Marketou, Emmanouil Foukarakis","doi":"10.1967/s002449912601","DOIUrl":"10.1967/s002449912601","url":null,"abstract":"<p><strong>Objective: </strong>The purpose of this study was to evaluate the contribution of single photon emission computed tomography/computed tomography (SPECT/CT) standardized uptake value (SUV) metrics in classifying patients with suspected transthyretin cardiac amyloidosis (ATTR-CA) among the different Perugini grades.</p><p><strong>Subjects and methods: </strong>One hundred four patients suspected of ATTR-CA underwent planar scintigraphy with bone seeking tracer (<sup>99m</sup>Tc pyrophosphate-PYP). Patients were classified according to the Perugini scale, the H/CL, H/Bone and H/Bkg ratios. A subset of 48 patients received additional SPECT/CT. Single photon emission computed tomography/CT SUV quantitative parameters, of the heart, myocardium, lungs, liver, soft tissues, bone, and SUV ratios (SUV<sub>max</sub>myo, SUV<sub>max</sub>lungs, SUV<sub>max</sub>liver, SUV<sub>max</sub>bone and SUV<sub>max</sub>soft tissue ratios), were evaluated in order to investigate potential metrics that could more clearly differentiate Perugini grades.</p><p><strong>Results: </strong>A total of 33.7% of patients were considered grade 0, 34.6% grade 1 and 31.7% grade 2/3. A combination of H/CL >1.33 and H/Bone >0.85 showed the highest sensitivity 100%. Standardized uptake value-based metrics clearly differentiated grade 0 or 1 vs grades 2 or 3, whereas no significant difference was found between grades 0 and 1, or between grades 1 and 2. The combined cut-off values H/CL 1.33 and SUV<sub>max</sub>myo 2.88 yielded 100% sensitivity and 84.6% specificity in differentiating ATTR-CA positives vs negatives. The metric SUV<sub>max</sub>myo/SUV<sub>max</sub>liver was the best metric to classify patients with grade 1 as negative (grade 0) or positive (grade 2 or 3).</p><p><strong>Conclusion: </strong>Single photon emission computed tomography/CT SUV metrics could be complementary to planar scintigraphy in classifying patients among the different Perugini grades. The ratio SUV<sub>max</sub>myo/SUV<sub>max</sub>liver was the only parameter with high affinity to differentiate patients with grade 1, as grade 0 or grade 2/3 for ATTR-CA.</p>","PeriodicalId":12871,"journal":{"name":"Hellenic journal of nuclear medicine","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138803053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The role of 18F-FDG PET/CT imaging in paediatric Langerhans disease: Case report. 18F-FDG PET/CT 成像在小儿朗格汉斯病中的作用:病例报告。
IF 1.5 4区 医学
Hellenic journal of nuclear medicine Pub Date : 2023-09-01 DOI: 10.1967/s002449912611
Ioanna Sevaslidou, Periklis Papavasileiou, Maria Gavra, Margarita Baka, Sophia Polychronopoulou, Lida Gogou
{"title":"The role of <sup>18</sup>F-FDG PET/CT imaging in paediatric Langerhans disease: Case report.","authors":"Ioanna Sevaslidou, Periklis Papavasileiou, Maria Gavra, Margarita Baka, Sophia Polychronopoulou, Lida Gogou","doi":"10.1967/s002449912611","DOIUrl":"10.1967/s002449912611","url":null,"abstract":"<p><p>Langerhans cell histiocytosis (LCH) is a haematological disorder, affecting single or multiple organs, characterized by abnormal proliferation of Langerhans cells in children. Accurate tumour delineation (number of lesions, organs involved) is crucial for staging/re-staging, and follow-up (response to therapy). Conventional imaging techniques (computed tomography (CT), magnetic resonance imaging (MRI)) have been employed for initial diagnosis, staging and assessment of response to therapy focusing on the healing effect therapeutic protocols have on the disease. In this case report, whole-body positron emission tomography/computed tomography (PET/CT) was shown either to provide information on the metabolic activity of histiocytes, or identify lesions otherwise asymptomatic. It is clear that PET/CT, combining anatomic and metabolic information, provides data for accurate staging, therapeutic protocol selection and assessment of response to therapy.</p>","PeriodicalId":12871,"journal":{"name":"Hellenic journal of nuclear medicine","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139039756","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
18F-FDG PET/CT image of pericardial inflammatory myofibroblastic tumor. 心包炎性肌纤维母细胞瘤的 18F-FDG PET/CT 图像。
IF 1.5 4区 医学
Hellenic journal of nuclear medicine Pub Date : 2023-09-01 Epub Date: 2023-12-14 DOI: 10.1967/s002449912608
Shuang Deng, Liu Xiao, Yuhao Li
{"title":"<sup>18</sup>F-FDG PET/CT image of pericardial inflammatory myofibroblastic tumor.","authors":"Shuang Deng, Liu Xiao, Yuhao Li","doi":"10.1967/s002449912608","DOIUrl":"10.1967/s002449912608","url":null,"abstract":"<p><p>Pericardial inflammatory myofibroblastic tumor (IMT) is very rare. Herein, we report fluorine-18-fluorodeoxyglucose (<sup>18</sup>F-FDG) positron emission tomography/computed tomography (PET/CT) findings of pericardial IMT in a 57-year-old woman. On conventional image, it presented as a pericardial mass with heterogeneous delay enhancement. On <sup>18</sup>F-FDG PET/CT image, this lesion had mild <sup>18</sup>F-FDG uptake with a maximum standardized uptake value (SUV<sub>max</sub>) of 1.84. The postoperative pathology supported a diagnosis of IMT. Our case hints us that IMT should be regarded as a differential diagnosis when we meet a solitary pericardial mass with <sup>18</sup>F-FDG uptake.</p>","PeriodicalId":12871,"journal":{"name":"Hellenic journal of nuclear medicine","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138802894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信